Andrew Coop, associate dean of academic affairs and professor at the University of Maryland School of Pharmacy, holds a small container of UMB425, a synthetic opioid painkiller he developed with Alex MacKerell, director of UM's Computer-Aided Drug Design Center. Unlike other prescription opioids, Coop says, the experimental drug will not cause physical dependency.
Andrew Coop, associate dean of academic affairs and professor at the University of Maryland School of Pharmacy, holds a small container of UMB425, a synthetic opioid painkiller he developed with Alex MacKerell, director of UM's Computer-Aided Drug Design Center. Unlike other prescription opioids, Coop says, the experimental drug will not cause physical dependency. Tony Pugh McClatchy
Andrew Coop, associate dean of academic affairs and professor at the University of Maryland School of Pharmacy, holds a small container of UMB425, a synthetic opioid painkiller he developed with Alex MacKerell, director of UM's Computer-Aided Drug Design Center. Unlike other prescription opioids, Coop says, the experimental drug will not cause physical dependency. Tony Pugh McClatchy

Could this experimental synthetic opioid break the cycle of addiction?

August 01, 2016 6:00 AM